Allergy Therapeutics
Allergy Therapeutics, a leading specialist in allergy immunotherapy, is headquartered in the United Kingdom and operates extensively across Europe and North America. Founded in 2003, the company has established itself as a pioneer in the development of innovative allergy treatments, focusing on both the diagnosis and management of allergic conditions. The firm’s core offerings include a range of allergy vaccines and immunotherapy products, distinguished by their unique formulations and patient-centric approach. Allergy Therapeutics is committed to advancing the field of allergy treatment, evidenced by its robust pipeline and significant clinical milestones. With a strong market position, the company continues to make strides in improving patient outcomes and enhancing the quality of life for those affected by allergies.
DitchCarbon Score
How does Allergy Therapeutics's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Allergy Therapeutics's score of 34 is higher than 54% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Allergy Therapeutics's reported carbon emissions
In 2024, Allergy Therapeutics reported total carbon emissions of approximately 2,687,000 kg CO2e. This figure reflects a significant decrease from 2023, when emissions were about 4,291,000 kg CO2e, comprising 431,000 kg CO2e from Scope 1, 1,901,000 kg CO2e from Scope 2, and 1,959,000 kg CO2e from Scope 3. In 2022, the company recorded total emissions of around 4,040,000 kg CO2e, with similar scope breakdowns: 437,000 kg CO2e (Scope 1), 1,742,000 kg CO2e (Scope 2), and 1,861,000 kg CO2e (Scope 3). The 2021 emissions were reported at about 3,017,000 kg CO2e, with Scope 1 emissions of 129,000 kg CO2e and Scope 2 emissions of 1,305,000 kg CO2e. Notably, the company has not disclosed any specific reduction targets or initiatives as part of its climate commitments, nor does it appear to have cascaded data from a parent organization. Allergy Therapeutics has demonstrated a commitment to transparency in its emissions reporting, but further details on reduction strategies or climate pledges are currently unavailable.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | |
|---|---|---|---|
| Scope 1 | 129,000 | 000,000 | 000,000 |
| Scope 2 | 2,273,000 | 0,000,000 | 0,000,000 |
| Scope 3 | 614,000 | 0,000,000 | 0,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Allergy Therapeutics is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
